logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals granted European patent

During 2018, Paradigm will release the results of its two phase II arthritis clinical trials.

files with a title of Patents
The company is well funded for the medium to long term

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has been granted a European patent for the treatment of bone marrow edema lesions with the drug pentosan polysulfate sodium (PPS).

The European registration solidifies global patent protection.

The granting of the European patent now means Paradigm has intellectual property rights in the major pharmaceutical markets of the U.S, Japan and Europe.

READ: Paradigm Biopharmaceuticals funded into 2019 through placement

During this calendar year, Paradigm will release the results of its two phase II arthritis clinical trials.

Granted patents in Europe, U.S. and Japan along with data from two phase II clinical trials provides a solid foundation for future plans including partnering discussions.

The benefits of drug repurposing

Paradigm is a biotechnology company focused on repurposing PPS, an FDA-approved drug that has a long track record of safely treating inflammation.

Paradigm is repurposing PPS for a number of applications with a focus on treatment of orthopaedic and viral arthritic indications.

Drug repurposing has the benefits of being lower cost, minimises risk and accelerated development timelines.

Paradigm’s strategy is to establish commercial partnerships with multiple leading pharmaceutical companies.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 3.26 AUD

ASX:PAR
Market: ASX
Market Cap: $732.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read